Pathway to precision and Equity

Overview
Precision without equity is incomplete. This branch integrates predictive analytics with biological equity, operationalizing sex‑linked biology and other hidden variables to improve fairness and performance in radiotherapy. Our work spans mathematical modeling, biomarker and nomogram development, and policy‑relevant analyses that expose and correct systemic blind spots.

Focus Areas

• Sex‑chromosome biology & divergence: Quantifying how male–female biology shapes tumour behavior and RT outcomes.

• Predictive modeling & decision support: Dynamics‑aware tumor response modeling; biomarkers and nomograms for clinical decisions.

• Equity in evidence & practice: Representation audits, guideline contributions, and needs assessments for underserved groups.

Flagship Publications (Selected)

• Sex‑Linked Biology & Equity

  • Radiotherapy cancer patient: female inclusive, but male dominated (Int J Radiat Biol, 2020) — Landmark analysis revealing systemic under‑interrogation of sex biology in RT.

  • SBRT kidney sex representation review (cTRO, 2025) — Evidence base and equity critique in disease‑specific RT research.

  • In silico analysis of survival with YBX1 in male and female solid tumours (Sci Rep, 2024) — Demonstrated sex‑contingent biomarker associations.

  • Evaluation of sex‑linked genes and treatment response in lung cancer (Radiother Oncol, 2025) — Establishes sex‑linked genes as quantifiable drivers of treatment response.

• Predictive Modeling & Vision

  • Predicting individual tumor response dynamics in LA‑NSCLC RT: mathematical modelling study (IJROBP, 2024) — Next‑gen response models linking biology to dose dynamics.

  • A joint physics & radiobiology DREAM team vision (Radiother Oncol, 2024) — International roadmap for better response prediction.

  • Research trends in RBE: bibliometric study (Radiat Res, 2024) — Landscape analysis informing modeling priorities.

• Biomarkers, Nomograms & Personalization

  • YB‑1: The key to personalised prostate cancer management? (Cancer Lett, 2020).

  • Nomograms are key decision‑making tools in prostate cancer RT (Urol Oncol, 2018).

  • Personalisation of RT prescriptions in LA‑NSCLC (Radiother Oncol, 2018).

• Practice, Implementation & Inclusion

  • Investigating the needs and concerns of LGBTQ+ cancer patients (J Homosex, 2024/2025).

  • Practical recommendations for radiodermatitis management (Radiat Oncol, ESTRO RTT, 2025).

  • Prehabilitation for patients undergoing RT: scoping review (Clin Oncol, 2024).

Methods & Tooling

• Pan‑cancer transcriptomics and sex‑chromosome analytic pipelines.

• Dynamics‑aware mathematical models for tumor response prediction.

• Biomarker evaluation frameworks with sex‑specific performance testing.

• Mixed‑methods and equity audits to align evidence generation with fair clinical translation.

Impact

• Define sex biology as measurable: Proposed sex chromosomes genes as biomarker of outcome.

• Built prediction‑to‑practice bridges: From modeling and biomarkers to guideline‑relevant implementation.

• Advanced equity in RT research: Exposed representational gaps and informed sex/gender‑aware study design and policy.

Get Involved

• We collaborate on sex‑aware analytics, modeling‑driven trials, and equity‑focused guideline development. Partners from data science, translational labs, and clinical oncology are welcome.